肝性脑病的微生物组治疗
本文综述了靶向肠道微生物组的肝性脑病治疗策略,包括益生元、益生菌、粪菌移植、抗生素、后生元和吸附剂等。乳果糖和利福昔明已取得一定成功,益生菌和粪菌移植也显示出前景,但微生物组的稳定性和临床结局不可预测仍是挑战。未来需关注严谨的试验设计、治疗选择及个体化方法。
要点
- 微生物-宿主相互作用在肝性脑病发病中起重要作用。
- 乳果糖和利福昔明是已有一定成功的微生物组靶向治疗。
- 益生菌和粪菌移植显示前景,但微生物组稳定性和结局预测仍是挑战。
核心结论
- 靶向微生物组的肝性脑病治疗已取得一些成功,但有效应用仍面临挑战。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 益生元、益生菌和粪菌移植用于增加潜在有益菌群,抗生素用于减少潜在有害菌群。
- 后生元和吸附剂等其他微生物组疗法用于靶向微生物产物。
- 乳果糖和利福昔明已取得一定成功,益生菌和粪菌移植也显示出前景。
- 微生物组对可持续变化的抵抗力和微生物群改变带来的不可预测临床结局仍是挑战。
临床怎么用
- 未来工作应关注严谨的试验设计、微生物组疗法的选择以及肝性脑病的个体化方法。
局限性
- 微生物组对可持续变化的抵抗力以及微生物群改变带来的不可预测临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatic encephalopathy (HE) is a complication of cirrhosis characterised by neuropsychiatric and motor dysfunction. Microbiota-host interactions play an important role in HE pathogenesis. Therapies targeting microbial community composition and function have been explored for the treatment of HE. Prebiotics, probiotics and faecal microbiota transplant (FMT) have been used with the aim of increasing the abundance of potentially beneficial taxa, while antibiotics have been used to decrease the abundance of potentially harmful taxa. Other microbiome therapeutics, including postbiotics and absorbents, have been used to target microbial products. Microbiome-targeted therapies for HE have had some success, notably lactulose and rifaximin, with probiotics and FMT also showing promise. However, there remain several challenges to the effective application of microbiome therapeutics in HE, including the resilience of the microbiome to sustainable change and unpredictable clinical outcomes from microbiota alterations. Future work in this space should focus on rigorous trial design, microbiome therapy selection, and a personalised approach to HE.
引用
- Bloom PP, Tapper EB, Young VB, et al. Microbiome therapeutics for hepatic encephalopathy. J Hepatol. 2021. PMID: 34453966. doi:10.1016/j.jhep.2021.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。